Cargando…

2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae

BACKGROUND: Colistin is considered as one of the last resort of antibiotics against carbapenem-resistant enterobacteriaceae. During the last decade, increased use of colistin or polymyxins due to the increasing prevalence of carbapenem-resistant Gram-negative bacteria has unfortunately led to the em...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Sara, Mahmood, Syed Faisal, Sharif, Fatima, Aijaz, Mariam, Awan, Safia, Jamil, Bushra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253246/
http://dx.doi.org/10.1093/ofid/ofy210.2099
_version_ 1783373453728940032
author Ahmed, Sara
Mahmood, Syed Faisal
Sharif, Fatima
Aijaz, Mariam
Awan, Safia
Jamil, Bushra
author_facet Ahmed, Sara
Mahmood, Syed Faisal
Sharif, Fatima
Aijaz, Mariam
Awan, Safia
Jamil, Bushra
author_sort Ahmed, Sara
collection PubMed
description BACKGROUND: Colistin is considered as one of the last resort of antibiotics against carbapenem-resistant enterobacteriaceae. During the last decade, increased use of colistin or polymyxins due to the increasing prevalence of carbapenem-resistant Gram-negative bacteria has unfortunately led to the emergence of colistin-resistant strains. There are no defined antibiotic regimens for colistin-resistant strains which makes the treatment of these organisms extremely challenging. We therefore report the clinical spectrum and outcomes of infections due to colistin-resistant carbapenem-resistant Enterobacteriaceae (Co-CRE) as well as the factors associated with acquisition of co-CRE. METHODS: We conducted a retrospective cross-sectional study from January 2013 till December 2017 on patients admitted to a tertiary care hospital in Karachi, Pakistan. Statistical analysis was done using SPSS 19. RESULTS: Forty patients with Co-CRE were identified of which 29 (72.5%) were males. Median age was 54.5 years. The most common organism isolated was Klebsiella in 22 (55%) followed by Providencia in 5 (12.5%) patients. Most common source of infection was the lung in 12 (30%) followed by urine in 11 (27.5%) patients. Similarly, the most common cause of bacteremia was pneumonia followed by intra-abdominal infections (50% and 37.5% of bacteremia cases, respectively). Twenty-eight (70%) patients had prior cultures with multi-drug-resistant organisms and 36 (90%) had used antibiotics in the past. A quarter (10) patients had pan resistant co-CRE strains while of the remaining strains 66% were sensitive to Fosfomycin. All patients received Colistin-based regimen in combination with 2 or 3 of the following: carbapenem, Fosfomycin, Amikacin, co-triamoxazole, and tigecycline. Complete clinical cure was achieved in only 50% of patients whereas microbiological eradication was achieved in 75%. Higher PITT bacteremia score, solid-organ transplant, and acute kidney injury were associated with mortality in patients with co-CRE. CONCLUSION: Infections with co-CRE was seen in patients with prior nosocomial exposures and led to poor outcomes, despite combination treatment guided by susceptibilities. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253246
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62532462018-11-28 2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae Ahmed, Sara Mahmood, Syed Faisal Sharif, Fatima Aijaz, Mariam Awan, Safia Jamil, Bushra Open Forum Infect Dis Abstracts BACKGROUND: Colistin is considered as one of the last resort of antibiotics against carbapenem-resistant enterobacteriaceae. During the last decade, increased use of colistin or polymyxins due to the increasing prevalence of carbapenem-resistant Gram-negative bacteria has unfortunately led to the emergence of colistin-resistant strains. There are no defined antibiotic regimens for colistin-resistant strains which makes the treatment of these organisms extremely challenging. We therefore report the clinical spectrum and outcomes of infections due to colistin-resistant carbapenem-resistant Enterobacteriaceae (Co-CRE) as well as the factors associated with acquisition of co-CRE. METHODS: We conducted a retrospective cross-sectional study from January 2013 till December 2017 on patients admitted to a tertiary care hospital in Karachi, Pakistan. Statistical analysis was done using SPSS 19. RESULTS: Forty patients with Co-CRE were identified of which 29 (72.5%) were males. Median age was 54.5 years. The most common organism isolated was Klebsiella in 22 (55%) followed by Providencia in 5 (12.5%) patients. Most common source of infection was the lung in 12 (30%) followed by urine in 11 (27.5%) patients. Similarly, the most common cause of bacteremia was pneumonia followed by intra-abdominal infections (50% and 37.5% of bacteremia cases, respectively). Twenty-eight (70%) patients had prior cultures with multi-drug-resistant organisms and 36 (90%) had used antibiotics in the past. A quarter (10) patients had pan resistant co-CRE strains while of the remaining strains 66% were sensitive to Fosfomycin. All patients received Colistin-based regimen in combination with 2 or 3 of the following: carbapenem, Fosfomycin, Amikacin, co-triamoxazole, and tigecycline. Complete clinical cure was achieved in only 50% of patients whereas microbiological eradication was achieved in 75%. Higher PITT bacteremia score, solid-organ transplant, and acute kidney injury were associated with mortality in patients with co-CRE. CONCLUSION: Infections with co-CRE was seen in patients with prior nosocomial exposures and led to poor outcomes, despite combination treatment guided by susceptibilities. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253246/ http://dx.doi.org/10.1093/ofid/ofy210.2099 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Ahmed, Sara
Mahmood, Syed Faisal
Sharif, Fatima
Aijaz, Mariam
Awan, Safia
Jamil, Bushra
2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae
title 2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae
title_full 2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae
title_fullStr 2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae
title_full_unstemmed 2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae
title_short 2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae
title_sort 2446. clinical spectrum and outcomes of colistin-resistant carbapenem-resistant enterobacteriaceae
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253246/
http://dx.doi.org/10.1093/ofid/ofy210.2099
work_keys_str_mv AT ahmedsara 2446clinicalspectrumandoutcomesofcolistinresistantcarbapenemresistantenterobacteriaceae
AT mahmoodsyedfaisal 2446clinicalspectrumandoutcomesofcolistinresistantcarbapenemresistantenterobacteriaceae
AT shariffatima 2446clinicalspectrumandoutcomesofcolistinresistantcarbapenemresistantenterobacteriaceae
AT aijazmariam 2446clinicalspectrumandoutcomesofcolistinresistantcarbapenemresistantenterobacteriaceae
AT awansafia 2446clinicalspectrumandoutcomesofcolistinresistantcarbapenemresistantenterobacteriaceae
AT jamilbushra 2446clinicalspectrumandoutcomesofcolistinresistantcarbapenemresistantenterobacteriaceae